[Form 4] GT Biopharma Inc. Insider Trading Activity
GT Biopharma director David C. Mun-Gavin acquired 31,250 shares of common stock by exercising options with a $1.33 exercise price. The reported transaction lists an acquisition of 31,250 option shares that convert to 31,250 common shares, and the filer notes the options are fully vested and exercisable.
The ownership after the reported transaction is 31,250 shares held directly. The filing is a standard Section 16 disclosure by an insider documenting option exercise and resulting beneficial ownership.
David C. Mun-Gavin, amministratore di GT Biopharma, ha acquisito 31.250 azioni ordinarie esercitando opzioni con prezzo di esercizio di 1,33 $. La segnalazione indica l’acquisto di 31.250 opzioni convertibili in 31.250 azioni ordinarie e specifica che le opzioni sono pienamente maturate ed esercitabili.
Alla data della transazione segnalata, la detenzione risulta pari a 31.250 azioni detenute direttamente. Il deposito è una normale informativa ai sensi della Sezione 16 da parte di un insider che documenta l’esercizio di opzioni e la conseguente titolarità effettiva.
David C. Mun-Gavin, director de GT Biopharma, adquirió 31.250 acciones ordinarias al ejercer opciones con un precio de ejercicio de 1,33 $. La notificación indica la adquisición de 31.250 opciones que se convierten en 31.250 acciones ordinarias y aclara que las opciones están totalmente consolidadas y son ejercitables.
Tras la transacción notificada, la propiedad es de 31.250 acciones en posesión directa. El documento es una divulgación estándar según la Sección 16 realizada por un insider que registra el ejercicio de opciones y la consiguiente tenencia beneficiaria.
GT 바이오파마 이사 데이비드 C. 문-개빈은 행사 가격 1.33달러의 옵션을 행사하여 보통주 31,250주를 취득했습니다. 보고된 거래는 31,250주의 옵션 취득을 기록하고 있으며, 이 옵션은 31,250주의 보통주로 전환되며 완전히 권리가 확정되어 행사 가능하다고 명시하고 있습니다.
보고된 거래 이후 보유 내역은 직접 보유한 31,250주입니다. 이 제출 서류는 내부자가 옵션 행사 및 그에 따른 실소유 지분을 문서화하기 위한 섹션 16의 표준 공시입니다.
David C. Mun-Gavin, administrateur de GT Biopharma, a acquis 31 250 actions ordinaires en exerçant des options à un prix d’exercice de 1,33 $. La transaction déclarée indique l’acquisition de 31 250 options convertibles en 31 250 actions ordinaires et précise que ces options sont entièrement acquises et exerçables.
Après la transaction déclarée, la détention s’élève à 31 250 actions détenues directement. Le dépôt constitue une divulgation standard au titre de la Section 16 par un initié documentant l’exercice d’options et la propriété bénéficiaire qui en résulte.
GT Biopharma-Direktor David C. Mun-Gavin erwarb 31.250 Stammaktien durch Ausübung von Optionen mit einem Ausübungspreis von 1,33 $. Die gemeldete Transaktion weist den Erwerb von 31.250 Optionsanteilen aus, die in 31.250 Stammaktien umgewandelt werden, und der Einreicher weist darauf hin, dass die Optionen vollständig unverfallbar sind und ausgeübt werden können.
Nach der gemeldeten Transaktion beträgt das Eigentum 31.250 direkt gehaltene Aktien. Die Meldung ist eine standardmäßige Offenlegung nach Section 16 durch einen Insider, die die Optionsausübung und das daraus resultierende wirtschaftliche Eigentum dokumentiert.
- Director exercised vested options, converting 31,250 options into 31,250 directly owned common shares
- Disclosure is complete regarding the nature of the transaction and vesting status, satisfying Section 16 reporting requirements
- None.
Insights
TL;DR: Insider exercised vested options to acquire 31,250 shares; routine disclosure of director activity with no governance red flags.
The Form 4 documents a straightforward exercise by a director of vested stock options into 31,250 common shares. The filer explicitly states the options are "fully vested and exercisable," indicating no vesting contingencies remain. This is a routine Section 16 disclosure that increases the director's direct beneficial ownership and aligns personal and shareholder interests. There is no indication of related-party transactions, unusual transfer restrictions, or changes to governance structure in the filing.
TL;DR: Director acquired 31,250 shares via option exercise at $1.33; the transaction increases insider share count but appears immaterial to public float.
The filing reports acquisition code "A" for an option to purchase common stock with a $1.33 exercise price for 31,250 options, resulting in 31,250 shares directly beneficially owned. The disclosure contains no additional transfers, sales, or derivative holdings. Absent information on total outstanding shares or prior insider holdings in this filing, the materiality of 31,250 shares to market capitalization cannot be assessed from this document alone. The entry is consistent with routine option exercises by insiders.
David C. Mun-Gavin, amministratore di GT Biopharma, ha acquisito 31.250 azioni ordinarie esercitando opzioni con prezzo di esercizio di 1,33 $. La segnalazione indica l’acquisto di 31.250 opzioni convertibili in 31.250 azioni ordinarie e specifica che le opzioni sono pienamente maturate ed esercitabili.
Alla data della transazione segnalata, la detenzione risulta pari a 31.250 azioni detenute direttamente. Il deposito è una normale informativa ai sensi della Sezione 16 da parte di un insider che documenta l’esercizio di opzioni e la conseguente titolarità effettiva.
David C. Mun-Gavin, director de GT Biopharma, adquirió 31.250 acciones ordinarias al ejercer opciones con un precio de ejercicio de 1,33 $. La notificación indica la adquisición de 31.250 opciones que se convierten en 31.250 acciones ordinarias y aclara que las opciones están totalmente consolidadas y son ejercitables.
Tras la transacción notificada, la propiedad es de 31.250 acciones en posesión directa. El documento es una divulgación estándar según la Sección 16 realizada por un insider que registra el ejercicio de opciones y la consiguiente tenencia beneficiaria.
GT 바이오파마 이사 데이비드 C. 문-개빈은 행사 가격 1.33달러의 옵션을 행사하여 보통주 31,250주를 취득했습니다. 보고된 거래는 31,250주의 옵션 취득을 기록하고 있으며, 이 옵션은 31,250주의 보통주로 전환되며 완전히 권리가 확정되어 행사 가능하다고 명시하고 있습니다.
보고된 거래 이후 보유 내역은 직접 보유한 31,250주입니다. 이 제출 서류는 내부자가 옵션 행사 및 그에 따른 실소유 지분을 문서화하기 위한 섹션 16의 표준 공시입니다.
David C. Mun-Gavin, administrateur de GT Biopharma, a acquis 31 250 actions ordinaires en exerçant des options à un prix d’exercice de 1,33 $. La transaction déclarée indique l’acquisition de 31 250 options convertibles en 31 250 actions ordinaires et précise que ces options sont entièrement acquises et exerçables.
Après la transaction déclarée, la détention s’élève à 31 250 actions détenues directement. Le dépôt constitue une divulgation standard au titre de la Section 16 par un initié documentant l’exercice d’options et la propriété bénéficiaire qui en résulte.
GT Biopharma-Direktor David C. Mun-Gavin erwarb 31.250 Stammaktien durch Ausübung von Optionen mit einem Ausübungspreis von 1,33 $. Die gemeldete Transaktion weist den Erwerb von 31.250 Optionsanteilen aus, die in 31.250 Stammaktien umgewandelt werden, und der Einreicher weist darauf hin, dass die Optionen vollständig unverfallbar sind und ausgeübt werden können.
Nach der gemeldeten Transaktion beträgt das Eigentum 31.250 direkt gehaltene Aktien. Die Meldung ist eine standardmäßige Offenlegung nach Section 16 durch einen Insider, die die Optionsausübung und das daraus resultierende wirtschaftliche Eigentum dokumentiert.
FAQ
What transaction did GTBP director David C. Mun-Gavin report on the Form 4?
What was the exercise price per share for the options exercised by the GTBP director?
How many shares does David C. Mun-Gavin beneficially own after the reported transaction?
Are the options that were exercised subject to further vesting conditions?
Does the Form 4 show any sales or dispositions by the reporting person?
